The development of new compounds to inhibit the replication of human immunodeficiency virus (HIV) relies on valid tissue culture and animal models of acquired immunodeficiency syndrome (AIDS). HIV has been successfully cultured in cells of human origin and transmitted to chimpanzees (1, 10-12, 15, 18, 20) . Although chimpanzees can be infected by HIV, the status of the animals as an endangered species and the fact that HIV does not appear to cause the fatal immunodeficiency syndrome in infected animals severely limit their usefulness (1, 11, 12) . Alternative animal models for AIDS are necessary to complement available tissue culture systems. One animal model that resembles AIDS closely is the simian immunodeficiency disease (SAIDS) associated with a related retrovirus (SIV/simian T-lymphotropic virus type III) isolated from rhesus macaques (9) . SIV has an approximately 40% nucleotide sequence homology with HIV type 1 (5) , and it causes in infected monkeys a fatal immune deficiency disease that is clinically similar to AIDS (9) . Thus, the SIV/macaque system represents an attractive animal model for the study of AIDS.
The viability of SIV/SAIDS as an animal model of HIV/ AIDS depends on the similarity of the biochemical functions of SIV to those of HIV. The hallmark of the retroviral life cycle is expression of reverse transcriptase activity in infected cells. Inhibition of the retroviral enzyme RNA-directed DNA polymerase (reverse transcriptase) is one approach toward treatment of AIDS (2-4, 8, 14, 19, 22) . An example of this approach is the drug 3'-azido-3'-deoxythymidine (AZT), which has clinical efficacy because in the nucleoside triphosphate form it preferentially inhibits viral reverse transcriptase (13, 19, 23 7 .0], 1 mM dithiothreitol, 10% glycerol) at 1:4 dilution for HIV (2-ml final volume) or 1:7 dilution for SIV (1.4-ml final volume) and applied to a single stranded-DNA-agarose column (1-ml packed volume equilibrated in column buffer). The enzyme activity was eluted with a gradient (100 ml) of 0 to 1.0 M NaCl in column buffer. Fractions (1 ml) were collected into tubes containing 200 ,ug of bovine serum albumin (10 ,ul of a 20-mg/ml solution), which improved enzymic stability. Activities, which eluted at 0.25 to 0.30 M NaCl, were collected and stored at -70°C.
The assay for reverse transcriptase measured the incorporation of tritiated deoxynucleoside triphosphate into an acid-precipitable form. The assay mixture (80 pul) contained 50 mM Tris hydrochloride (pH 8.0), 5 mM MgCl2, 150 mM KCl, 5 mM dithiothreitol, and labeled deoxynucleoside triphosphate. The template-primer concentration for [PH] thymidine incorporation was 15 ,uM poly(A)-oligo(dT) [12] [13] [14] [15] [16] [17] [18] (concentration in nucleotide base pairs); for [3H]deoxyguanosine incorporation, the concentration of poly(C)-oligo (dG)12_18 was 188 puM in nucleotide base pairs. The concentrations of the template primers were chosen to be saturating for the enzymes. The high concentration of poly(C)-oligo(dG)12_18 needed to achieve Vmax was observed for both SIV and HIV enzymes. Inhibitors were added as required.
After incubation at 37°C, 15-pdl samples were removed at various times and processed as described previously (7).
Enzymes for this study were prepared from viral lysates by DNA-agarose chromatography. The final preparations of reverse transcriptases were free of nuclease activities and yielded linear reaction kinetics for up to 80 min of incubation time. The preparations were free of other viral proteins based on immunoblotting (Western hybridization) with HIV antisera.
The nucleotides AZTTP, ddTTP, and ddGTP are potent inhibitors of HIV reverse transcriptase, with KmIKi ratios of 100 to 400 with respect to the corresponding deoxyribonucleoside triphosphates (6, 13, 21) . Inhibition data for the SIV enzyme have not been reported. The kinetics of inhibition of reverse transcriptases from SIV and HIV by ddGTP are shown in Fig. 1 . The data indicate the competitive nature of the inhibition by ddGTP with respect to dGTP and afford nearly equal Michaelis and inhibition constants for the two enzymes. The Kms of dGTP were 5.4 puM for the SIV enzyme and 4.7 puM for the HIV enzyme. The Kis of ddGTP were 0.011 and 0.009 puM for the SIV and HIV enzymes, respectively. The Km/Ki ratio for SIV reverse transcriptase was 490; for HIV, the ratio was 522.
The complete data for two primer templates and three inhibitors are summarized in Table 1 . For all substrates and inhibitors tested, the SIV reverse transcriptase had values of Km and Ki that were very similar to those of the HIV enzyme. The values determined for the enzyme from HIV were in good agreement with those reported previously (6, 13, 21) .
In addition to being potent competitive inhibitors of the enzymes, the compounds tested in this study are also chain terminators for the DNA polymerase reaction. Comparisons of chain termination for the two enzymes require further investigation.
In summary, the results indicate that the kinetic properties of reverse transcriptase from SIV are virtually identical to those of the enzyme from the human virus. In conjunction with data from animal studies, our data suggest that SIVinfected cells and animals are relevant models of AIDS and may be particularly suited to the development of drugs directed against HIV reverse transcriptase.
